Management of neuropathic pain: Translating mechanistic advances and evidence-based research into clinical practice

Clinical Journal of Pain

Volumn 22, Issue SUPPL. 1, 2006, Pages

  Gallagher, Rollin M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Evidence based; Management; Neuropathic pain

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BACLOFEN; CAPSAICIN; CARBAMAZEPINE; DESIPRAMINE; DEXTROMETHORPHAN; DULOXETINE; EMLA; GABAPENTIN; KETAMINE; LIDOCAINE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OMEGA CONOTOXIN MVIIA; OXCARBAZEPINE; OXYCODONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ANTIDEPRESSANT AGENT;

APPLICATION SITE BURNING; APPLICATION SITE REACTION; ATAXIA; BLURRED VISION; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIABETIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HUMAN; HYPOTENSION; HYPOTESTOSTERONE; INFECTION; META ANALYSIS; NAUSEA; NEUROENDOCRINE DISEASE; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; POLYPHARMACY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOMNOLENCE; SYSTEMATIC REVIEW; TRIGEMINUS NEURALGIA; VOMITING; WEIGHT GAIN; XEROSTOMIA; ALGORITHM; CLASSIFICATION; DEPRESSION; EVALUATION; METHODOLOGY; PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY;

ALGORITHMS; ANALGESICS; ANTIDEPRESSIVE AGENTS; DEPRESSION; EVALUATION STUDIES; EVIDENCE-BASED MEDICINE; HUMANS; PAIN; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33644874170     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ajp.0000193827.07453.d6     Document Type: Review

References (31)

1. Woolf CJ, Mannion RJ. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet. 1999;353:1959-1964.
2. Galer BS. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(suppl 9):S17-S25.
3. Flatters SJL, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150-161.
4. Lee SH, Kayser V, Desmeules J, et al. Differential action of morphine and various opioid agonists on thermal allodynia and hyperalgesia in mononeuropathic rats. Pain. 1994;57:233-240.
5. Tal M, Bennett GJ. Neuropathic pain sensations are differentially sensitive to dextrorphan. Neuroreport. 1994;5:1438-1440.
6. Xiao W-H, Bennett GJ. Synthetic v-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther. 1995;274:666-672.
7. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389-400.
8. Beydoun A, Backonja M-M. Mechanistic stratification of antineuralgic agents. J Pain Symptom Manage. 2003;25:S18-S30.
9. Coderre TJ, Kumar N, Lefebvre CD, et al. Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate. J Neurochem. 2005;94:1131-1139.
10. Rowbotham MC, Harden N, Stacey B, et al, Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia. A randomized controlled trial. JAMA. 1998;280:1837-1842.
11. Dubinsky RM, Kabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959-965.
12. Attal N, Brasseur L, Chauvin M, et al. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in post-herpetic neuralgia. Pain. 1999;81:203-209.
13. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs. 2004;64:937-947.
14. Litman SJ, Vitkun SA, Poppers PJ. Use of EMLA cream in the treatment of post-herpetic neuralgia. J Clin Anesth. 1996;8:54-57.
15. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151-158.
16. Peikert A, Hentrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol. 1991;238:452-456.
17. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44.
18. Zhang WY, Li Wan Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol. 1994;46:517-522.
19. Katz NP, Gammaitoni AR, Davis MW, et al, Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324-332.
20. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21:265-270.
21. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842-1846.
22. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain. A randomized trial in postherpetic neuralgia. Neurology. 1998;50:1837-1841.
23. Gallagher RM, Verma S. Mood and anxiety disorders in chronic pain. In: Dworkin RH, Brieghtbart W, eds. Psychosocial and Psychiatric Aspects of Pain: A Handbook for Health Care Providers. Progress in Pain Research and Management, Vol 27. Seattle: IASP Press, 2004.
24. Dohrenwend BP, Raphael KG, Marbach JJ, et al. Why is depression comorbid with chronic myofascial face pain? A family study test of alternative hypotheses. Pain. 1999;83:183-192.
25. Raphael KG, Janal MN, Nayak S, et al. Familial aggregation of depression in fibromyalgia: a community-based test of alternate hypotheses. Pain. 2004;110:449-460.
26. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Pyschiatry. 2001;178:234-241.
27. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia. A randomized, placebo-controlled trial. Neurology. 2002;59:1015-1021.
28. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215-224.
29. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anti-convulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20:449-458.
30. Gallagher RM, Verma S. Biopsychosocial pain medicine: integrating psychiatric and behavioral therapies into medical treatment. Sem Neurosurg. 2004;15:31-46.
31. Gallagher RM. Treatment planning in pain medicine: integrating medical, physical, and behavioral therapies. Med Clin North Am. 1999;83:823-849.